Previous 10 |
Thinly traded NuCana plc ( NCNA +2.7% ) is up on average volume following its corporate presentation at Citigroup's Annual Biotech Conference in Boston. The slides are not posted in its website, however. More news on: NuCana plc, Healthcare stocks news, Stocks on the move, Read mor...
EDINBURGH, United Kingdom, Aug. 29, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Fin...
NuCana (NASDAQ: NCNA ) Q2 results (£M): Net loss: (1.3) (+52.0%); cash and equivalents: 87.9 (-6.5%); cash burn: (6 mo.): (5.9) (-64.2%). More news on: NuCana plc, Healthcare stocks news, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...